Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Alza Concerta To Be Introduced At Discount To Ritalin-SR And Generics

Executive Summary

Alza will launch its once-daily methylphenidate Concerta at a discount to Novartis' twice-daily Ritalin-SR as well as generic forms of the sustained-release attention deficit/hyperactivity disorder drug.

You may also be interested in...



Ritalin Diversion From Schools Could Encourage Once-Daily ADHD Drugs

Methylphenidate diversion from schools is a major contributor to the supply of the drug in illicit channels, Drug Enforcement Administration Office of Diversion Control Deputy Director Terrance Woodworth told a May 16 hearing of the House Education and the Workforce/Early Childhood, Youth and Families Subcommittee.

Alza/McNeil Concerta 420-Rep Sales Force Will Target Peak October Season

Alza and McNeil Consumer Healthcare are preparing a combined sales force of 420 reps to detail Alza's once-daily methylphenidate treatment Concerta for pediatric attention deficit/hyperactivity disorder.

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036451

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel